INDIVIOR PHARMACEUTICALS INC (INDV) — insider trading
Health Care · NASDAQ
INDIVIOR PHARMACEUTICALS INC (INDV) has 17 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 17 (latest 2026-07-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Heidbreder Christian | Officer (Chief Scientific Officer) | Open-market sale | 18,586 | $41.14 | $764.6K | Form 4 |
| 2026-06-22 | Ciaffoni Joseph | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 1,266,903 | — | — | Form 4 |
| 2026-06-22 | Ciaffoni Joseph | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 612,549 | $38.32 | $23.47M | Form 4 |
| 2026-06-22 | Ciaffoni Joseph | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 1,266,903 | — | — | Form 4 |
| 2026-06-11 | Heidbreder Christian | Officer (Chief Scientific Officer) | Open-market sale | 18,586 | $38.06 | $707.4K | Form 4 |
| 2026-06-08 | Preblick Ryan | Officer (Chief Financial Officer) | Open-market sale | 36,000 | $37.70 | $1.36M | Form 4 |
| 2026-05-13 | Wheadon David E. | Director | Grant / award / vesting | 10,430 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Stejbach Mark | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Ryan Barbara | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-13 | NINIVAGGI DANIEL A | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Kingsley Stuart A | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Humphreys Keith | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-13 | Thompson Juliet | Director | Grant / award / vesting | 6,518 | $0.00 | $0 | Form 4 |
| 2026-05-12 | Thompson Juliet | Director | Shares withheld for taxes / exercise cost | 1,117 | $38.28 | $42.8K | Form 4 |
| 2026-03-14 | Preblick Ryan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 6,302 | — | — | Form 4 |
| 2026-03-14 | Preblick Ryan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 2,843 | $31.11 | $88.4K | Form 4 |
| 2026-03-14 | Preblick Ryan | Officer (Chief Financial Officer) | Option exercise / conversion | 6,302 | — | — | Form 4 |
Ask the chat about INDV's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: INDIVIOR PHARMACEUTICALS INC (INDV).
Last updated 2026-07-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.